Oxford BioMedica and a team of cancer immunologists from Cardiff University in Great Britain are collaborating to evaluate TroVax in a Phase I/II study for mesothelioma. The study aims to examine the effect of TroVax in combination with first-line chemotherapy agents Alimta and cisplatin as a treatment against malignant mesothelioma.
Mesothelioma is a rare, aggressive cancer primarily caused by exposure to airborne asbestos fibers. Symptoms of...
MarketWatch
Source: PR Newswire
May 17, 2010, 8:00 a.m. EDT
INDIANAPOLIS, May 17, 2010 /PRNewswire via COMTEX/ -- Eli Lilly and Company will unveil data from 57 studies at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Ill. from June 4 - 8, 2010, during which the company will present the latest research results on ALIMTA(R) (pemetrexed for injection) and GEMZAR(R) (gemcitabine HCl for injection), as well as ERBITUX(R) (cetuximab)...
General-Population Patients With NSCLC Respond to Salvage Chemotherapy With Pemetrexed: Presented at Lung 2010
Doctor's Guide
DGDispatch
By Jenny Powers
GENEVA -- May 3, 2010 -- Patients in the general population with non-small-cell lung cancer (NSCLC) receiving salvage chemotherapy with pemetrexed experienced equivalent response to those of patients in a selected population who participated in clinical trials, according to study results presented here at the...
Southwest Oncology Group and the National Cancer Institute are finalizing the Phase I/Randomized Phase II clinical trial "Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma." The trial studied the side effects and best dose of cediranib maleate when given together with pemetrexed disodium and cisplatin.
Rosetta Genomics Now Processing Fine-Needle Aspirate Cell Block Samples for Lung Cancer Subclassification
April 05, 2010 07:30 AM Eastern Daylight Time
Molecular test that helps determine treatment can now be performed before the tumor is surgically resected
Uses highly accurate microRNA-based technology of miRview™ squamous test on Fine-Needle Aspirate (FNA) cell block samples to subclassify non-small cell lung cancer (NSCLC)
